2018
A phase I study of palbociclib (PALBO) plus everolimus (EVE) and exemestane (EXE) in hormone-receptor positive (HR+)/HER2- metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i): safety, tolerability and pharmacokinetic (PK) analysis.
Barroso-Sousa R, Guo H, Barry W, Ferreira A, Rees R, Winer E, Wagle N, Tolaney S. A phase I study of palbociclib (PALBO) plus everolimus (EVE) and exemestane (EXE) in hormone-receptor positive (HR+)/HER2- metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i): safety, tolerability and pharmacokinetic (PK) analysis. Journal Of Clinical Oncology 2018, 36: 1068-1068. DOI: 10.1200/jco.2018.36.15_suppl.1068.Peer-Reviewed Original Research
1997
Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer: a phase II trial
Sutton L, Warmuth M, Petros W, Winer E. Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer: a phase II trial. Cancer Chemotherapy And Pharmacology 1997, 40: 335-341. PMID: 9225952, DOI: 10.1007/s002800050666.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerBreast cancerTrans retinoic acidSystemic exposureMonths durationClinical pharmacologyPharmacokinetic analysisInitial systemic exposureM2 three timesCycles of therapyPhase II studyPhase II trialRetinoic acidStable diseaseII trialTumor cytoreductionUnacceptable toxicityFirst doseII studyPartial responsePatient withdrawalProgressive diseaseTreatment regimenInitial doseSingle institution